Antioxidant and anti-Alzheimer's disease activities of 1,8-cineole and its cyclodextrin inclusion complex

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 175, P. 116784 - 116784

Published: May 22, 2024

1,8-Cineole is a bicyclic monoterpene widely distributed in the essential oils of various medicinal plants, and it exhibits significant anti-inflammatory antioxidant activities. We aimed to investigate therapeutic effect 1,8-cineole on anti-Alzheimer's disease by using transgenic Caenorhabditis elegans models. Our studies demonstrated that significantly relieved Aβ1–42-induced paralysis exhibited remarkable anti-Aβ1–42 aggregation activities nematodes CL4176, CL2006 CL2355. developed 1,8-cineole/cyclodextrin inclusion complex, displaying enhanced anti-paralysis, anti-Aβ compared 1,8-cineole. In addition, we found treatment activated SKN-1/Nrf-2 pathway induced autophagy nematodes. results 1,8-cineole, which provide potential approach for Alzheimer's disease.

Language: Английский

---

Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: July 17, 2024

Donepezil in combination with memantine is a widely used clinical therapy for moderate to severe dementia. However, real-world population data on the long-term safety of donepezil are incomplete and variable. Therefore, aim this study was analyze adverse events (AEs) according US Food Drug Administration Adverse Event Reporting System (FAERS) provide evidence monitoring therapy.

Language: Английский

---

Trajectory of brain-derived amyloid beta in Alzheimer’s disease: where is it coming from and where is it going?

Translational Neurodegeneration, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 19, 2024

Alzheimer's disease (AD) is a progressive neurological disorder that primarily impacts cognitive function. Currently there are no disease-modifying treatments to stop or slow its progression. Recent studies have found several peripheral and systemic abnormalities associated with AD, our understanding of how these alterations contribute AD becoming more apparent. In this review, we focuse on amyloid‑beta (Aβ), major hallmark summarizing recent findings the source brain-derived Aβ discussing where cleared in vivo. Based findings, propose future strategies for prevention treatment, from novel perspective metabolism.

Language: Английский

---

Advances in Understanding Biomarkers and Treating Neurological Diseases -Role of the Cerebellar Dysfunction and Emerging Therapies

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 102519 - 102519

Published: Sept. 1, 2024

Language: Английский

---

Computational Analysis of Stilbenes as Potential Multi-Targeted Therapeutics for Alzheimer’s Disease

Osmaniye Korkut Ata Üniversitesi Fen Bilimleri Enstitüsü Dergisi, Journal Year: 2025, Volume and Issue: 8(1), P. 145 - 166

Published: Jan. 15, 2025

Purpose: The aim of this study is to compare 13 stilbenes and 5 FDA-approved drugs used in the treatment Alzheimer’s disease (AD) by ADME prediction molecular docking method. Cholinergic, amyloid, tau, oxidative stress inflammation hypotheses involved AD pathology were targeted docking. Materials Methods: SwissADME has been determine physicochemical, lipophilicity, water solubility, pharmacokinetics, drug-likeness medicinal chemistry properties (resveratrol, pterostilbene, oxyresveratrol, piceatannol, pinosylvin, isorhapontigenin, isorhapontin, astringin, piceid (polydatin), mulberroside A) (tacrine, donepezil, rivastigmine, galantamine, memantine). CBDOCK2 binding affinity target proteins (AChE, BuChE, APP, BACE, GSK-3β, CDK5, SOD, CAT, GPx, Cox-2, iNOS, IL-1β, TNF-α). Results: SWISS results showed that could be as natural products AD. indicated A best vina score (kcal/mol) followed galanthamine, resveratrol, tacrine, memantine. Conclusion: Our evaluated for using computational approaches. highlight its potential therapeutic effects on various pathology. More research needed validate these findings clinical practice.

Language: Английский

---

Decoding the Role of Neurotrophins in Glycogen Synthase Kinase 3-Beta Regulation in Alzheimer’s Disease

Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

---

Yoga an integrated mind body intervention for improvement in quality of life in individuals with Alzheimer’s disease and their caregivers

Frontiers in Aging, Journal Year: 2025, Volume and Issue: 6

Published: March 21, 2025

Background and objective Alzheimer’s disease (AD) presents profound challenges, significantly impairing quality of life (QOL) for patients increasing the burden on caregivers. This study aims to investigate effectiveness a tailored 12-week yoga intervention in improving individuals with mild moderate AD reducing caregiver (CB). Methods is interventional healthy controls enrolled 30 participants (18 males, 12 females) diagnosed by an expert neurologist. Participants were aged 60 years or older recruited from old age home. A program, including specific postures (asanas), pranayama (breathing exercises), meditation, was conducted 1 hour daily, 6 days week. Neurocognitive assessments performed pre- post-intervention using Geriatric Depression Scale (GDS), Montreal Cognitive Assessment (MoCA), Caregiver Burden (CB) Scale. MoCA scores analyzed across domains, language, memory, attention, visuospatial ability, delayed recall, abstraction, orientation. Results The led significant improvements quality-of-life measures. GDS decreased 8.36 ± 2.79 5.13 3.07 (P < 0.01; 95% CI: −3.98 −2.31), while total improved 18.23 4.90 21.10 5.09 2.17–3.89). Domain-specific also showed enhancements, particularly recall. burden, measured CB Scale, demonstrated notable reductions following −2.54 −1.23). Conclusion underscores depression cognitive function, overall AD. Additionally, alleviated highlighting its potential as effective mind-body approach management.

Language: Английский

---

Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(3), P. e0309849 - e0309849

Published: March 24, 2025

Background Finasteride is commonly utilized in clinical practice for treating androgenetic alopecia, but real-world data regarding the long-term safety of its 0adverse events(AEs) remains incomplete, necessitating ongoing supplementation. This study aims to evaluate AEs associated with finasteride use, based on from US Food and Drug Administration Adverse Event Reporting System (FAERS), contribute assessment. Methods We reviewed AE reports database, covering period first quarter 2004 2024. assessed medication using four proportional disproportionality analyses: reported odds ratio (ROR), proportionate reporting (PRR), Bayesian Confidence Propagation Neural Network (BCPN), Multi-Item Gamma Poisson Shrinkage (MGPS). These methods were used whether there a significant association between drug use AEs. To investigate potential issues related we further analyzed similarities differences onset time by sex, as well age. Results A total 11,557 which was primary suspected analysed. The majority patients male (86.04%) proportion young adults aged 18-45 years (27.22%). 73 different categorised into 7 system organ classes (SOCs), common including erectile dysfunction sexual dysfunction. In addition, identified previously unlisted AEs, Peyronie’s disease post-5α reductase inhibitor syndrome. Of 102 occurred men women, depression anxiety being observed both sexes. When analysed age group, 17 ≤ 18 years, 157 18-65 133 ≥ 65 years. Common all groups included dysfunction, decreased libido, depression, suicidal ideation, psychotic disturbances attention disorders. median 61 days, occurring within month treatment. Notably, number persisted beyond one year Conclusion results our uncovered known novel medication. Some these identical specification, some them signaled that not demonstrated specification. showed variations sex study. Consequently, findings offer valuable insights future research are anticipated enhance safe practice.

Language: Английский

---

Engineered nanoparticles for the treatment of Alzheimer’s disease

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 3, 2025

Alzheimer’s disease (AD) is one of the most common diseases characterized by neurodegeneration and becoming a major public health problem worldwide. AD manifested mainly progressive impairments in cognition, emotion, language memory elderly population. Many treatment strategies have been explored for decades; however, there still no effective way to address root cause pathogenesis, only target symptoms improve patient cognitive outcomes. Intracerebral administration difficult because challenges posed blood‒brain barrier (BBB). NPs are materials with sizes between 1 100 nm that can biocompatibility, extend half-life, transport macromolecules, be delivered across BBB central nervous system, exhibit good targeting capabilities. provide new ideas terms their antiaging, antineuroinflammatory, antioxidative, nerve repair-promoting effects. In this manuscript, we first describe relationship BBB. Second, introduce application nanoparticles treatment. Finally, summarize faced AD.

Language: Английский

---

Weighted Visibility Graph-based Deep Complex Network Features: New Diagnostic Spontaneous Speech Markers of Alzheimer's Disease

Physica D Nonlinear Phenomena, Journal Year: 2025, Volume and Issue: unknown, P. 134681 - 134681

Published: April 1, 2025

Language: Английский

---